$STRO

SUTRO BIOPHARMA, INC. (STRO): Submission of Matters to a Vote of Security Holders

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001382101 0001382101 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2

Original reporting
Published Jun 8, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:46 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$STRO
Neutral
medium confidence
Mentioned
$STRO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STRONeutralLow
01

Why it matters

The disclosure confirms the board nominees were elected, Ernst & Young LLP was ratified as independent auditor for 2026, and the advisory say-on-pay proposal passed (non-binding).

02

Market read

Provides verified governance outcomes that may slightly influence sentiment but lacks new operating/financial catalysts.

03

What to watch

Traders may instead focus on whether any director contests or say-on-pay opposition could foreshadow future activism or changes in compensation strategy, though no such signal is quantified beyond vote counts here.

Relevance 6/10Novelty 5/10Timing: after-hours / filed June 8, 2026

Background

The article is an SEC Form 8-K (Item 5.07) reporting the outcomes of Sutro Biopharma’s 2026 annual stockholder meeting held June 5, 2026.

Company-level read

Ticker impact

$STRONeutralMedium confidence
Context

Sutro Biopharma filed an 8-K detailing results of its June 5, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment around governance outcomes.

Evidence & confidence

The filing is a primary SEC disclosure of voting results, but it does not include new financial guidance, clinical data, or material transactions.

Market effects

Minimal read-across; governance vote outcomes are generally company-specific for small/mid-cap biopharma.

None.

None.

Counterpoint

Because the items are standard (director election, auditor ratification, non-binding say-on-pay), the market may ignore the details unless vote margins signal broader shareholder dissatisfaction.

Key entities

  • Sutro Biopharma, Inc.

    Nasdaq-listed biopharma company filing the 8-K with annual meeting voting results.

  • Ernst & Young LLP

    Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.

Related articles

$STROMed

SUTRO BIOPHARMA, INC. (STRO): Results of Operations and Financial Condition

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 stro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favora

$BACMed

Bank of America pledges US$250B for U.S. infrastructure financing

Bank of America said it will deploy $250 billion by July 2027 under its “Critical Infrastructure Finance Initiative” to finance U.S. digital and infrastructure projects. The bank plans primary lending, investments, capital markets services, and advisory across digital infrastructure, energy and power, and core infrastructure. It said the target is measured from Jan 1, 2026 to July 4, 2027.

$APVOMedAI 8/10

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics (NASDAQ:APVO) said it will induce holders to exercise existing common warrants for cash at a $4.03 exercise price, issuing inducement warrants for up to 1,274,610 shares. Separately, it plans a PIPE selling up to 861,708 shares (or pre-funded warrants) plus common warrants for up to 4,308,540 shares, also at $4.03. Gross proceeds total about $4.5 million, for working capital.

$GMMed

GM sets up $4.5 billion supply chain prepayment facility

General Motors said in a regulatory filing that it set up a $4.5 billion supply-chain prepayment facility with Procura Auto Parts LLC. Procura will prepay GM suppliers for inventory, funded by a bank syndicate including JPMorgan Chase and Banco Santander. GM will repay via irrevocable payment undertakings after inventory is used, no later than Aug. 6, 2029.

$INTCHighAI 9/10

Intel Is Raising Billions in Equity. History Says This Is What the Stock Will Do Next.

Intel (INTC) announced a $15 billion all-stock equity offering, reported after market close to be upsized to $20 billion, with banks able to buy an extra $3 billion. The article links this to Intel’s prior CHIPS Act equity conversion and earlier equity sales involving Nvidia (NVDA) and SoftBank (SFTBY). It discusses potential uses including fab buildout and possible buyouts of Brookfield’s stakes.

$WIAMed

Wia fully funded to advance Namibia project following DFS completion, MRE increase

Wia Gold (ASX-listed) says it has firm commitments for an A$125 million placement to fund the Kokoseb gold project in Namibia after completion of its definitive feasibility study. The DFS reported maiden probable ore reserves of 69.8 Mt at 0.87 g/t (1.95 Moz) and forecast 150,000 oz/y for 10 years. Funding is conditional on shareholder approval; first gold is targeted for Q4 2028.